Takeda Halts Domestic Phase III AMG479 Trial For Pancreatic Cancer
This article was originally published in PharmAsia News
Takeda Pharmaceuticals announced Aug. 9 it decided to halt Phase III trials of the antibody drug AMG479 (ganitumab) for pancreatic cancer.
You may also be interested in...
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.